Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00695578 · ClinicalTrials.gov registry record · Phase 4

Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy

A Phase 4 study of Actinic Keratosis, sponsored by Wake Forest University.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT00695578 is a Phase 4 study of Actinic Keratosis that has completed, run by Wake Forest University. The registered enrollment target is 20 participants, below the 188-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00695578, a Phase 4 study of Actinic Keratosis, has completed, sponsored by Wake Forest University.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to evaluate the use of Biafine Cream on wounds created by removal of actinic keratosis using cryotherapy in a clinical setting.

Conditions Studied

Interventions

  • DRUG Biafine
  • DRUG Polysporin

Study Locations (1)

North Carolina

  • Wake Forest University Health Sciences Dermatology - Winston-Salem

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2006-10
Est. Completion 2008-02
Phase Phase 4

Sponsor

Wake Forest University

100 total trials

What the Registry Record Tells You About NCT00695578

The ClinicalTrials.gov registry entry for NCT00695578 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (89% lower). The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Actinic Keratosis appearing as the primary indexed condition, and to 2 interventions - of which Biafine is the first listed.

NCT00695578 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00695578 about?

NCT00695578 is a clinical study titled "Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy". The purpose of this research study is to evaluate the use of Biafine Cream on wounds created by removal of actinic keratosis using cryotherapy in a clinical setting.

What is the current status of trial NCT00695578?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2006-10. Estimated completion is 2008-02.

What conditions does trial NCT00695578 study?

This clinical trial studies the following conditions: Actinic Keratosis.

What interventions are being tested in trial NCT00695578?

The interventions under investigation include: Biafine (DRUG), Polysporin (DRUG).

Who is sponsoring clinical trial NCT00695578?

This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00695578 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Actinic Keratosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.